Ilona C. Enninga
Chief Executive Officer at Amphera BV
Profile
Ilona C.
Enninga is currently the Chief Executive Officer at Amphera BV.
Prior to this, she held the position of Technical Director at Charles River Laboratories Den Bosch BV from 1992.
Enninga has also worked as a Research Associate at the University of Leiden, Chief Operating Officer at Immunovo BV, and Head-Genetic & Environmental Toxicology at Charles River Laboratories Den Bosch BV.
Enninga received her undergraduate degree in 1981 and her doctorate in 1986 from the University of Leiden.
Ilona C. Enninga active positions
| Companies | Position | Start |
|---|---|---|
| Charles River Laboratories Den Bosch BV | Chief Tech/Sci/R&D Officer | 31/12/1991 |
Amphera BV
 Amphera BV BiotechnologyHealth Technology Amphera BV develops an immunotherapy for cancer induced by asbestos. It triggers the patient?s own immune defense system, growth of cancer cells may be stopped or inhibited. The company was founded in December 2012 and is headquartered s-Hertogenbosch, the Netherlands. | Chief Executive Officer | - |
Former positions of Ilona C. Enninga
| Companies | Position | End |
|---|---|---|
| University of Leiden | Corporate Officer/Principal | - |
| Charles River Laboratories Den Bosch BV | Corporate Officer/Principal | - |
Immunovo BV
 Immunovo BV BiotechnologyHealth Technology Immunovo BV develops immune therapeutics in the field of oncology. The firm's research focuses on therapeutic vaccines based on synthetic peptide antigens for which the company applies the novel and proprietary techniques in synthetic immunogen development. Its products include Sclerostin, PD1, PEPA10-adj, Gastrine, VEGF, and GnRH. The company was founded in 2009 and is headquartered in ‘s-Hertogenbosch, the Netherlands. | Chief Operating Officer | - |
Training of Ilona C. Enninga
| University of Leiden | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Immunovo BV
Immunovo BV BiotechnologyHealth Technology Immunovo BV develops immune therapeutics in the field of oncology. The firm's research focuses on therapeutic vaccines based on synthetic peptide antigens for which the company applies the novel and proprietary techniques in synthetic immunogen development. Its products include Sclerostin, PD1, PEPA10-adj, Gastrine, VEGF, and GnRH. The company was founded in 2009 and is headquartered in ‘s-Hertogenbosch, the Netherlands. | Health Technology |
| Charles River Laboratories Den Bosch BV | |
Amphera BV
Amphera BV BiotechnologyHealth Technology Amphera BV develops an immunotherapy for cancer induced by asbestos. It triggers the patient?s own immune defense system, growth of cancer cells may be stopped or inhibited. The company was founded in December 2012 and is headquartered s-Hertogenbosch, the Netherlands. | Health Technology |
- Stock Market
- Insiders
- Ilona C. Enninga
